×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ACRV – acrivon therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ACRV
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/14
11:13 am
acrv
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its price target lowered by analysts at BMO Capital Markets from $28.00 to $27.00. They now have an "outperform" rating on the stock.
Low
Report
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its price target lowered by analysts at BMO Capital Markets from $28.00 to $27.00. They now have an "outperform" rating on the stock.
11/14
08:15 am
acrv
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
Medium
Report
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
11/13
07:00 am
acrv
Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
Medium
Report
Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
10/17
08:00 am
acrv
Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium
Medium
Report
Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium
10/16
04:00 pm
acrv
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/11
08:00 am
acrv
Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity
Low
Report
Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity
9/16
10:09 am
acrv
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $17.00 price target on the stock.
Medium
Report
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $17.00 price target on the stock.
9/16
09:13 am
acrv
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $28.00 price target on the stock, up previously from $25.00.
High
Report
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $28.00 price target on the stock, up previously from $25.00.
Date
Time
Symbol
Company Name
Action
%Chg
11/13/2024
07:00 am
acrv
acrivon therapeutics, inc.
MISS
Report
-6.4%
acrivon therapeutics, inc.
8/13/2024
08:00 am
acrv
acrivon therapeutics, inc.
BEAT
Report
-4.5%
acrivon therapeutics, inc.
5/14/2024
07:31 am
acrv
acrivon therapeutics, inc.
BEAT
Report
-1.4%
acrivon therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
9/16
10:09 am
Reiterates
Market Outperform
Market Outperform
JMP Securities
Medium
Report
-8.6%
9/16
10:09 am
Reiterates
Market Outperform
Market Outperform
JMP Securities
Medium
Report
-8.6%
9/16
09:43 am
Reiterates
Market Outperform
Market Outperform
JMP Securities
High
Report
-10.5%
9/16
09:43 am
Reiterates
Market Outperform
Market Outperform
JMP Securities
High
Report
-10.5%
Date
Time
Symbol
Headline
Impact
11/18
04:32 pm
acrv
Form 4 Acrivon Therapeutics, For: Nov 14 Filed by: Miller Mary
Low
Report
Form 4 Acrivon Therapeutics, For: Nov 14 Filed by: Miller Mary
11/18
04:32 pm
acrv
Form 4 Acrivon Therapeutics, For: Nov 14 Filed by: Peterson Katharine
Low
Report
Form 4 Acrivon Therapeutics, For: Nov 14 Filed by: Peterson Katharine
11/18
04:31 pm
acrv
Form 4 Acrivon Therapeutics, For: Nov 14 Filed by: Holm-Jorgensen Rasmus
Low
Report
Form 4 Acrivon Therapeutics, For: Nov 14 Filed by: Holm-Jorgensen Rasmus
11/18
04:30 pm
acrv
Form 4 Acrivon Therapeutics, For: Nov 14 Filed by: Gamelin Erick
Low
Report
Form 4 Acrivon Therapeutics, For: Nov 14 Filed by: Gamelin Erick
11/18
04:29 pm
acrv
Form 4 Acrivon Therapeutics, For: Nov 14 Filed by: Devroe Eric
Low
Report
Form 4 Acrivon Therapeutics, For: Nov 14 Filed by: Devroe Eric
11/18
04:27 pm
acrv
Form 4 Acrivon Therapeutics, For: Nov 14 Filed by: Blume-Jensen Peter
Low
Report
Form 4 Acrivon Therapeutics, For: Nov 14 Filed by: Blume-Jensen Peter
11/13
07:06 am
acrv
Form 10-Q Acrivon Therapeutics, For: Sep 30
Medium
Report
Form 10-Q Acrivon Therapeutics, For: Sep 30
11/13
07:00 am
acrv
Form 8-K Acrivon Therapeutics, For: Nov 13
Medium
Report
Form 8-K Acrivon Therapeutics, For: Nov 13
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: